Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

The synbiotic mixture of Bacillus licheniformis and Saccharomyces cerevisiae extract aggravates dextran sulfate sodium induced colitis in rats.

Tytuł:
The synbiotic mixture of Bacillus licheniformis and Saccharomyces cerevisiae extract aggravates dextran sulfate sodium induced colitis in rats.
Autorzy:
Salem GA; Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, P.O. Box 44519, Zagazig, Egypt. gamal_vet_.
Mohamed AA; Departments of Forensic Medicine and Toxicology and Faculty of Veterinary Medicine, Zagazig University, Zagazig, 44519, Egypt.
Ghonimi WAM; Department of Histology and Cytology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, 44519, Egypt.
Abdallah HM; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, 44519, Egypt.
Rhouma NR; Department of Micobiology, Faculty of Science, Misurata University, Misurata, P.O. Box 2478, Libya.
Ali RI; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Banha University, Banha, 13518, Egypt.
Źródło:
BMC veterinary research [BMC Vet Res] 2022 Nov 16; Vol. 18 (1), pp. 405. Date of Electronic Publication: 2022 Nov 16.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, 2005-
MeSH Terms:
Bacillus licheniformis*
Synbiotics*
Colitis*/chemically induced
Colitis*/therapy
Colitis*/metabolism
Colitis*/veterinary
Humans ; Rats ; Animals ; Dextran Sulfate/toxicity ; Saccharomyces cerevisiae ; Sulfasalazine/adverse effects ; Rats, Sprague-Dawley
References:
Gastroenterol Res Pract. 2019 Nov 03;2019:5363261. (PMID: 31781191)
Dig Dis Sci. 1997 Apr;42(4):824-32. (PMID: 9125657)
Vet J. 2010 Jul;185(1):23-7. (PMID: 20621712)
Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73. (PMID: 20101257)
Biomed Res Int. 2017;2017:6742652. (PMID: 29018816)
Int Immunopharmacol. 2003 Dec;3(13-14):1731-41. (PMID: 14636824)
Clin Exp Allergy. 2003 Dec;33(12):1634-40. (PMID: 14656348)
Dis Colon Rectum. 2007 Jul;50(7):1061-9. (PMID: 17429712)
Gut. 1991 Jan;32(1):50-4. (PMID: 1846838)
Front Microbiol. 2021 May 18;12:623739. (PMID: 34084155)
Food Res Int. 2020 Feb;128:108679. (PMID: 31955779)
Exp Ther Med. 2017 Dec;14(6):6069-6073. (PMID: 29285159)
Scand J Gastroenterol. 1998 Jun;33(6):628-36. (PMID: 9669636)
J Zhejiang Univ Sci B. 2008 Apr;9(4):341-50. (PMID: 18381811)
Redox Biol. 2015 Dec;6:617-639. (PMID: 26520808)
Curr Opin Crit Care. 2002 Apr;8(2):145-51. (PMID: 12386516)
Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S1-13. (PMID: 14989423)
Br J Nutr. 2012 Nov 14;108(9):1633-43. (PMID: 22243836)
Immunopharmacology. 1990 Nov-Dec;20(3):217-24. (PMID: 1981213)
J Nutr. 2007 Nov;137(11 Suppl):2563S-2567S. (PMID: 17951503)
Dig Dis Sci. 1993 Sep;38(9):1722-34. (PMID: 8359087)
Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):102-107. (PMID: 28724171)
Food Funct. 2019 Jan 22;10(1):397-409. (PMID: 30604793)
Clin Infect Dis. 2015 May 15;60 Suppl 2:S129-34. (PMID: 25922398)
J Crohns Colitis. 2008 Mar;2(1):24-62. (PMID: 21172195)
Lancet. 2009 May 30;373(9678):1905-17. (PMID: 19482216)
Immunol Allergy Clin North Am. 2019 Feb;39(1):63-79. (PMID: 30466773)
Cytokine. 2016 Jul;83:189-192. (PMID: 27155817)
PLoS One. 2012;7(9):e43910. (PMID: 22970150)
J Dairy Sci. 2019 Nov;102(11):9570-9585. (PMID: 31477303)
Benef Microbes. 2019 May 28;10(5):543-553. (PMID: 31122042)
Med Mycol. 2021 Apr 06;59(4):335-344. (PMID: 32598443)
J Vet Med B Infect Dis Vet Public Health. 2003 Oct;50(8):412-6. (PMID: 14633213)
Nat Rev Immunol. 2014 May;14(5):329-42. (PMID: 24751956)
PLoS One. 2020 Mar 17;15(3):e0228846. (PMID: 32182248)
Drug Des Devel Ther. 2020 Mar 13;14:1127-1141. (PMID: 32214798)
Res Microbiol. 2000 Jun;151(5):361-8. (PMID: 10919516)
Drugs. 2006;66(10):1371-87. (PMID: 16903771)
Sci Transl Med. 2017 Mar 8;9(380):. (PMID: 28275154)
Gut Microbes. 2011 Sep 1;2(5):280-6. (PMID: 22067939)
Inflamm Bowel Dis. 2011 Jan;17(1):362-81. (PMID: 20725949)
BMC Gastroenterol. 2004 Mar 15;4:5. (PMID: 15113451)
Inflammation. 2019 Oct;42(5):1680-1691. (PMID: 31115770)
Nutr Res. 2015 Dec;35(12):1106-12. (PMID: 26500083)
Gastroenterology. 2009 Apr;136(4):1182-97. (PMID: 19249397)
J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):170-3. (PMID: 16629949)
Dig Dis Sci. 2008 Sep;53(9):2495-506. (PMID: 18157694)
BMC Complement Altern Med. 2011 Apr 28;11:34. (PMID: 21527003)
Sci Rep. 2020 Mar 24;10(1):5345. (PMID: 32210304)
Vet Immunol Immunopathol. 2007 Feb 15;115(3-4):299-308. (PMID: 17157391)
Aliment Pharmacol Ther. 2013 Oct;38(8):854-63. (PMID: 23981095)
Biomed Pharmacother. 2018 Aug;104:366-374. (PMID: 29778019)
Nutrients. 2019 Apr 27;11(5):. (PMID: 31035617)
Dis Colon Rectum. 2002 May;45(5):621-7. (PMID: 12004211)
Probiotics Antimicrob Proteins. 2017 Sep;9(3):292-299. (PMID: 28083809)
World J Gastroenterol. 2008 Jul 21;14(27):4280-8. (PMID: 18666314)
Poult Sci. 2021 Sep;100(9):101358. (PMID: 34358955)
Gastroenterology. 2006 Jun;130(7):1962-74. (PMID: 16762619)
Food Chem Toxicol. 2014 Jul;69:294-302. (PMID: 24788059)
Front Microbiol. 2022 Feb 07;13:801827. (PMID: 35197953)
PLoS One. 2009 Sep 16;4(9):e7056. (PMID: 19756155)
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4623-30. (PMID: 21282652)
Gastroenterology. 1990 Mar;98(3):694-702. (PMID: 1688816)
Sci Rep. 2016 Sep 23;6:34132. (PMID: 27658624)
N Engl J Med. 2009 Jun 4;360(23):2467-70. (PMID: 19494224)
Am J Health Syst Pharm. 2010 Mar 15;67(6):449-58. (PMID: 20208051)
Int J Colorectal Dis. 2012 Nov;27(11):1445-53. (PMID: 22562255)
Gastroenterology. 2017 Feb;152(2):309-312. (PMID: 27960091)
Therap Adv Gastroenterol. 2009 Mar;2(2):99-108. (PMID: 21180538)
World J Gastroenterol. 2014 Sep 7;20(33):11505-24. (PMID: 25206258)
Curr Opin Gastroenterol. 2005 Jul;21(4):426-30. (PMID: 15930982)
World J Gastroenterol. 2012 May 21;18(19):2344-56. (PMID: 22654425)
Front Physiol. 2021 Jan 18;11:577237. (PMID: 33536931)
Gut. 2005 Feb;54(2):242-9. (PMID: 15647189)
J Anim Sci. 2017 Jun;95(6):2627-2639. (PMID: 28727032)
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):431-6. (PMID: 15625114)
Mol Ther Nucleic Acids. 2020 Mar 6;19:731-740. (PMID: 31945730)
Poult Sci. 2021 Dec;100(12):101506. (PMID: 34731741)
Methods Enzymol. 1990;186:729-42. (PMID: 2172726)
Gastroenterology. 2001 Mar;120(4):827-33. (PMID: 11231936)
Curr Gene Ther. 2012 Dec;12(6):484-92. (PMID: 23061565)
Infect Immun. 2004 Jun;72(6):3299-309. (PMID: 15155633)
Cochrane Database Syst Rev. 2020 Mar 4;3:CD005573. (PMID: 32128795)
J Nutr Biochem. 2020 May;79:108353. (PMID: 32145470)
Biomed Pharmacother. 2020 May;125:109949. (PMID: 32058216)
Ann Pharmacother. 2007 Jul;41(7):1284-7. (PMID: 17595302)
Food Funct. 2020 Apr 30;11(4):3459-3470. (PMID: 32239008)
Gastroenterology. 2004 Feb;126(2):520-8. (PMID: 14762789)
N Engl J Med. 2002 Aug 8;347(6):417-29. (PMID: 12167685)
Evid Based Complement Alternat Med. 2020 Jan 30;2020:5659738. (PMID: 32082397)
Dig Dis Sci. 2013 May;58(5):1244-9. (PMID: 23306840)
Inflamm Bowel Dis. 2006 Jul;12(7):581-7. (PMID: 16804395)
Curr Med Sci. 2019 Jun;39(3):371-378. (PMID: 31209805)
Dig Dis Sci. 2008 Apr;53(4):954-63. (PMID: 17934835)
J Clin Invest. 2019 Nov 1;129(11):4691-4707. (PMID: 31566580)
Appl Environ Microbiol. 2005 Feb;71(2):968-78. (PMID: 15691955)
Carcinogenesis. 2013 Dec;34(12):2833-41. (PMID: 24064222)
Inflamm Bowel Dis. 2008 Aug;14(8):1147-53. (PMID: 18286647)
Am J Gastroenterol. 2005 Jul;100(7):1539-46. (PMID: 15984978)
Adv Drug Deliv Rev. 2007 Sep 30;59(11):1073-83. (PMID: 17825455)
Gut. 1998 Feb;42(2):214-9. (PMID: 9536946)
Clin Exp Immunol. 2010 Nov;162(2):306-14. (PMID: 20731672)
FEMS Microbiol Rev. 2005 Sep;29(4):813-35. (PMID: 16102604)
Life Sci. 2020 Jan 1;240:117089. (PMID: 31759038)
J Leukoc Biol. 2004 May;75(5):764-71. (PMID: 14966192)
Chem Biol Interact. 2007 Oct 20;170(1):40-8. (PMID: 17681286)
Biomed Pharmacother. 2019 Jan;109:1688-1697. (PMID: 30551423)
Microorganisms. 2022 Apr 29;10(5):. (PMID: 35630380)
Poult Sci. 2016 May;95(5):1173-8. (PMID: 26944966)
Contributed Indexing:
Keywords: IL-1β; INFγ; Prebiotic; Probiotic; TNFα; Ulcerative colitis
Substance Nomenclature:
9042-14-2 (Dextran Sulfate)
3XC8GUZ6CB (Sulfasalazine)
Entry Date(s):
Date Created: 20221117 Date Completed: 20221121 Latest Revision: 20240102
Update Code:
20240102
PubMed Central ID:
PMC9667625
DOI:
10.1186/s12917-022-03479-y
PMID:
36384756
Czasopismo naukowe
Background: Uncertain effects of probiotics and/or prebiotics have been reported in experimental and clinical colitis. This study aims to examine the effects of a synbiotic combination comprising Bacillus licheniformis DSM 17236 and Saccharomyces cerevisiae cell wall extract on dextran sulfate sodium (DSS)-induced colitis in Sprague Dawley rats.
Methods: Acute colitis was induced in rats by oral administration of DSS 3.5% for 7 days. Fifty rats were divided equally into five groups; one control group and the other groups were induced with colitis and treated with or without the tested synbiotic, mixed with diet, for 28 days and sulfasalazine (100 mg/kg) via intragastric tube once daily for 14 days.
Results: Symptomatically, the synbiotic administration raised the disease activity index (DAI) to comparable scores of the DSS group, specially from the 2nd to 7th days post DSS intoxication. It also induced a significant (p < 0.05) amplification of WBCs, myeloperoxidase (MPO), malondialdehyde (MDA), nuclear factor kappa B (NF-kB) expression and proinflammatory cytokines tumor necrosis factor alpha (TNFα), interferon gamma (INFγ), and interleukin-1 beta (IL-1β) while depressed the antioxidant enzymes glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) when compared with the DSS and control groups. The DSS intoxicated and Synbiotic+DSS groups showed desquamations of the covering epithelium, noticeable diffuse leukocytic infiltrations, sever catarrhal enteritis, ischemic colitis with diffuse coagulative necrosis of the entire colonic mucosa. Contrarily, sulfasalazine proved to be effective in the reduction of the tested inflammatory markers and the pathological degenerative changes of the DSS ulcerative colitis.
Conclusion: The examined synbiotic did not ameliorate but aggravated the DSS-induced colitis, so it should be subjected to intensive experimental and clinical testing before their use in animals and human.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies